PPARGC1A and neoplasm: A tool compound, XCT790, which inhibits the ERRα-PGC1 signaling pathway, was deployed to disrupt mitochondrial biogenesis; it was effective in reducing OxPhos in tumor-initiating stem-like cells in breast cancers [161].